Cindy Lanzendoen

Recent Posts

Champions Oncology Partners with Puma Biotechnology and NSABP Foundation on Metastatic Breast and Colon Cancer Co-clinical PDX Studies

Jun 18, 2018 5:25:35 PM / by Cindy Lanzendoen

Hackensack, NJ – June 18, 2018 – Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that they have partnered with NSABP Foundation, Inc. (formerly National Surgical Adjuvant Breast and Bowel Project) and Puma Biotechnology, Inc. (Nasdaq: PBYI) to develop patient derived xenograft (PDX) models in two multi-center co-clinical PDX trials.

Read More →

Champions Oncology to Host Webinar on Patient-Derived Xenograft Program for Clinical Advancement

Feb 11, 2016 11:20:43 AM / by Cindy Lanzendoen

Hackensack, NJ - February 11, 2016 – Champions Oncology (CSBR) announced today that it will host a live, complimentary webinar titled, “Patient Derived Xenograft Program for Clinical Advancement”, on Monday, February 29, from 1:30 AM to 2:30 PM Eastern Time. The webinar will feature Neal Goodwin, PhD, Vice President of Corporate Research Development at Champions Oncology.

Read More →

Champions Oncology Announces Initiation of Prospective Correlative Trial in Sarcoma

Jan 21, 2016 11:00:28 AM / by Cindy Lanzendoen

Hackensack, NJ – January 21, 2016 – Champions Oncology (NASDAQ : CSBR) today announced that it has initiated a sponsored prospective correlative trial of patient derived xenograft modeling (PDX or Champions TumorGraft® PDX models) in patients with metastatic or recurrent sarcoma.  Mount Sinai Hospital in Toronto, Canada is the first clinical site to enroll patients in the newly-opened study.

Read More →